Latest news with #AmericanAcademyofDermatologyAnnualMeeting
Yahoo
07-03-2025
- Business
- Yahoo
Eli Lilly (NYSE:LLY) Achieves Breakthrough Efficacy With EBGLYSS for Atopic Dermatitis in Long-Term Study
Eli Lilly saw a notable 10% increase in its stock price over the last month, driven by several important events. Central to this rise was the encouraging long-term efficacy data for its drug EBGLYSS in treating atopic dermatitis, presented at the American Academy of Dermatology Annual Meeting. Supported by FDA approval in 2024, this product has bolstered investor confidence in the company's innovative pipeline. Additionally, positive earnings results for Q4 2024, with sales reaching $13.53 billion, played a key role, as did the European Medicines Agency's positive outlook on Jaypirca for chronic lymphocytic leukemia. Amid a broader market slump, with major indexes like the Dow and S&P 500 on track for significant weekly losses, Eli Lilly's performance stands out, driven by these strategic developments and robust financial results, showcasing resilience in a volatile economic climate. Click here to discover the nuances of Eli Lilly with our detailed analytical report. Over the past 5 years, Eli Lilly has achieved a very large total shareholder return of 670.12%, a reflection of its transformative journey. The company's development of Mounjaro, FDA-approved in 2022 for type 2 diabetes management, showcased its capacity for innovation. Moreover, strategic partnerships like the April 2022 collaboration with Genesis Therapeutics, valued at US$20 million, have bolstered its growth trajectory. The substantial US$2.1 billion investment in 2022 to expand manufacturing facilities in Indiana further underscored Eli Lilly's commitment to enhancing its production capabilities. Despite its high-priced earnings multiple compared to peers, the company's earnings growth over 2024 surpassed both industry and market benchmarks. In the context of recent performance, it's important to highlight that Eli Lilly's one-year return outpaced both the US Pharmaceuticals industry and the broader market, which saw much smaller returns. This strong performance, coupled with a 15% increase in dividends announced in December 2024, reflects the company's robust earnings growth and ability to maintain investor confidence even amid broader market challenges. Learn how Eli Lilly's intrinsic value compares to its market price with our detailed valuation report. Gain insight into the risks facing Eli Lilly and how they might influence its performance—click here to read more. Already own Eli Lilly? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:LLY. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
07-03-2025
- Health
- Yahoo
Artax Biopharma Presents New Preclinical Data on Nck Modulators at 2025 AAD Annual Meeting
Nck modulator reduced evidence of inflammation in an animal model of dermal irritation Compelling preclinical data support continued development of Nck modulators in atopic dermatitis CAMBRIDGE, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announced the presentation of new preclinical data in atopic dermatitis models with Nck modulators, in an ePoster with oral presentation at the 2025 American Academy of Dermatology Annual Meeting, taking place March 7-11, in Orlando, Florida. 'These preclinical results highlight the potential breadth and depth of Nck modulation, a completely novel mechanism which we believe has the potential to achieve true immunomodulation for a broad range of autoimmune conditions,' said Dr. Rob Armstrong, Chief Executive Officer of Artax Biopharma. 'On the heels of our recently announced positive Phase 2a data in patients living with psoriasis, we look forward to continuing to evaluate the potential of Nck modulation to impact TCR signaling activation in response to self-antigens and offer an alternative to broad immunosuppression for patients with serious autoimmune diseases.' ePoster presentation 'TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Dermatologic Diseases,' Christopher L. VanDeusen, PhD; Shannon Dwyer; D. Scott Batty Jr, MD; Aldo Borroto, PhD; Andrés P Gagete, PhD; Robert W. Armstrong, PhD; Balbino Alarcón, PhD Dysregulated TCR signaling leads to T-cell-mediated autoimmune diseases. Nck modulators specifically block Nck recruitment upon TCR activation, correcting erroneous activation. Nck plays a fundamental role in increased TCR signaling triggered by self-antigens, which is a key upstream event in autoimmune diseases. Nck modulators act by modulating T cell activation, rather than broadly suppressing it. Key findings include: Dose-dependent decrease in dust mite induced cytokine production from peripheral blood mononuclear cells (PBMCs) isolated from an atopic dermatitis patient. Treatment of healthy PBMCs with AX-158 resulted in a dose-dependent reduction in cytokine release across all T helper cell subtypes including IL-17, IL-4 and IL-13. Oral Nck modulator AX-194 significantly reduced the appearance of inflammation in an imiquimod model of dermal irritation, as demonstrated by reduction in the total number of hematopoietic cells and inflammatory macrophages in the skin. Based on this preclinical evidence, the Artax team is planning further studies in additional autoimmune diseases to explore the potential of Nck modulators to correct erroneous T cell activation in dermal autoimmune disorders. About Artax BiopharmaArtax Biopharma is a clinical-stage biotechnology company transforming the treatment of T Cell-driven autoimmune diseases. Artax's first-in-class oral small molecules aim to deliver immune system modulation without immunosuppression, potentially unlocking new treatment options as both monotherapy and in combination with other treatments. Artax Biopharma is based in the Boston area and raised funding from investors including Advent Life Sciences, Sound Bioventures, The Termeer Family Office, the Fuhrer Family Office and Columbus Venture Partners. For more info, see or follow us on LinkedIn. About Nck modulation We believe there is significant potential for Nck modulation to revolutionize treatment of T Cell-driven diseases. Immunomodulation maintains healthy control of the immune system, while addressing the underlying source of T Cell-driven diseases. Central to a well-functioning immune system is the T Cell Receptor (TCR). When TCR signaling becomes dysregulated, it causes T Cell-driven conditions, including autoimmune diseases. We believe the immunomodulation mechanism offered by our investigational agents holds broad potential to revolutionize how these T Cell-driven autoimmune diseases are addressed, while not impairing the ability of a patient's immune system to function properly. AX-158, our lead Nck modulator, has shown strong, broad cytokine modulation as well as modulation of mixed lymphocyte reactions. Good data on therapeutic efficacy with AX-158 were observed in murine models of self-antigen activation (EAE), with a prolonged pharmacodynamic effect in EAE, suggesting durable immune modulation. AX-158 showed no immunosuppression in models of strong antigen stimulation. Studies with AX-158 showed substantial preclinical evidence of activity in the Th2, Th17, Th1/Th0 pathways, suggesting that applications could be quite broad across the autoimmune space. For future clinical study inquiries: contact@ Contacts: Maria Nichol, DPhil, EPA, CPA Chief Business Officer mnichol@ Media: Madelin HawtinLifeSci Communicationsmhawtin@ in to access your portfolio
